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How did the study come about?
The hepatitis C virus, formerly classified as ‘non-A non-B’
hepatitis virus, was identified in 1989.1 This blood-borne virus
is endemic worldwide, with an estimated 170 million persons
chronically infected, representing approximately 3% of the
world population.2 Long-term morbidity associated with persis-
tent hepatitis C virus infection includes the development of
cirrhosis and primary liver cancer.
The Swiss Hepatitis C Cohort Study (SCCS) is a joint effort
between the Swiss Group of Experts in Viral Hepatitis and the
Swiss Association for the Study of the Liver. The SCCS was
established because large population-based cohort studies are
the only way to confirm or refute working hypotheses on the
natural course of chronic hepatitis C and on hepatitis C virus
pathology, and partly because experience with a similar
collaborative effort of specialized treatment centres had already
been successfully established for a human immunodeficiency
virus cohort in Switzerland.3–9 Therefore, the aims of the SCCS
were to set up an infrastructure and investigative network
fostering clinical and biomedical research on the natural history
of hepatitis C virus infection and to optimize and standardize
the management and treatment of hepatitis C virus-infected
patients. The cohort is expected to add information on factors
that shape progression of hepatitis C virus infection, thus
informing future therapeutic decisions and predictions of the
burden of hepatitis C virus-related diseases at the population
level, as well as supplementing epidemiological data collected
by the mandatory national surveillance system at the Swiss
Federal Office of Public Health. Ethical approval for data
collection was obtained from each hospital’s ethics committee.
Recruitment for the SCCS began in September 2000, with initial
funding from the Swiss Group of Experts in Viral Hepatitis.
Since April 2001, funding of the core structure has been
largely provided by the Swiss National Science Foundation.
Additional sources of funding, for both the core structure and
the scientific nested projects, have been provided over the years
by several public and private institutions, including the Swiss
Office for Education and Science and the European
Commission.
What does it cover?
The SCCS collects standardized prospective information on
adults with confirmed hepatitis C virus infection through
questionnaires, clinical examination and laboratory investiga-
tions conducted at eight centres providing specialist treatment
across Switzerland. Since its inception, the SCCS has evolved to
include nested scientific projects to answer a range of questions
such as the correlation of expression levels of PP2Ac (protein
phosphatase 2, catalytic subunit, alpha isoform) in the liver and
pattern of response to interferon-alpha-based therapy, or the
significance of connective tissue growth factor in the progres-
sion of disease in patients with chronic hepatitis C.
Who is in the sample?
Adult patients aged 18 years and over, who were confirmed
hepatitis C virus antibody positive by immunoblot, with no
exclusion criteria other than age less than 18 years. From
1 September 2000, the start of recruitment, until 31 December
2005, a total of 2452 persons had been enrolled into the
cohort, contributing a total of 4239 person years of follow-up
(to 30 June 2006).
The eight centres cover all regions of the country and include
all five university teaching hospitals in Switzerland (Basel,
Bern, Geneva, Lausanne, Zurich) and three major cantonal
hospitals (Lugano, Neuchaˆtel and St.Gallen). A number of
satellite centres (smaller regional hospitals) or investigators
(practising physicians; mostly gastroenterologists) are asso-
ciated with each of the eight main centres, thus forming a
second level of local networks.* Corresponding author. E-mail: zwahlen@ispm.unibe.ch
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Patient characteristics
Table 1 shows selected characteristics of participants at
enrolment. The median age at enrolment was 42 years (inter-
quartile range, 35–50 years; Table 1). Fifty-eight per cent were
in the 25–44 year age-group, similar to the proportion observed
in the mandatory reporting system (61%, based on
cumulative figures from 1988 to 2005). The median time
since diagnosis of hepatitis C virus infection was 3.7 years
(inter-quartile range, 0.9–7.8), with 58% having been diagnosed
0–5 years prior to enrolment.
Most participants in the SCCS were males (63%), whites
(95%) and of Swiss nationality (75%). The majority were
educated to apprenticeship/high-school level (51%) and were in
paid or unpaid employment (64%). The most commonly
reported hepatitis C virus risk factor (more than one could be
reported per person) was a history of injection drug use (57%),
with time of starting injecting drugs being on average 17 years
(inter-quartile range, 12–23 years) before enrolment. Only 231
participants (9.4%) had no risk factor recorded. Cross-
tabulation of the risk factors showed that injection drug use
and transfusion were also mentioned in 28% and 54%,
respectively, of those reporting an invasive medical procedure.
Infection with hepatitis C virus genotype 1 was the most
common (46%), followed by genotype 3 (27%). Thirty-nine
per cent had ever been infected with hepatitis B virus of whom
4.8% (45/946) were hepatitis B surface antigen positive; 8%
were co-infected with human immunodeficiency virus. About
two-thirds (64%) of the SCCS participants were hepatitis C
virus ribonucleic acid positive at enrolment, and a raised
alanine transaminase was found in 1498 persons (61%).
Overall, 38% had an alanine transaminase ratio in the range
of41.0–2.5 times the upper end of normal.
How often have they been followed up?
Participants have been followed up at 6–12 monthly intervals at
which time standardized follow-up information is collected
covering events and behaviours since the last visit. If a patient
did not return for the scheduled follow-up visit, then his/her
treating physician sent the patient at least two further written
invitations to attend before they were considered lost to follow-
up. A ‘Stop Form’ was completed, when the patient was either
lost to follow-up or had died. Cause of death was coded
according to the ICD 10 classification.10
What has been measured?
At enrolment
A standardized enrolment questionnaire was completed by
patients’ physicians or a study nurse. The information was
largely taken from medical notes but for some questions,
e.g. concerning quality of life, it was obtained by a face-to-face
interview. Other items of information collected included
ethnicity, drinking habits, employment, income, history of
certain pre-specified hepatitis C virus infection risk events or
behaviours and whether or not the patient had had previous
hepatitis C virus treatment (Table 2).
Patients also had a physical examination, which could lead
to a liver biopsy being performed. The results of a clinically
Table 1 Selected baseline (enrolment) characteristics of all SCCS
participants compared with those who were cirrhotic: 1 September
2000–31 December 2005
Variable description
Total number (%)
(n¼ 2452)
Cirrhotics (%)
(n¼ 339)
Age at enrolment (years)
Median (inter-quartile range) 42 (35–50) 50 (44–59)
Age at diagnosis (years)
Median (inter-quartile range) 37 (30–46) 45 (38–54)
Gender
Male 1555 (63) 247 (73)
Ethnic group
White 2323 (95) 323 (95)
Nationality
Swiss 1830 (75) 239 (71)
Education(highest completed)
No higher/short term professional 803 (33) 109 (32)
Apprenticeship/matura 1251 (51) 167 (49)
Higher including university 366 (15) 59 (17)
Missing 32 (1.3) 4 (1.2)
Employment status
Employment (paid or unpaid) 1570 (64) 195 (58)
Unemployed 254 (10) 19 (5.6)
Retired or other situation 613 (25) 124 (37)
Missing 15 (0.6) 1 (0.29)
Income per year (in CHF)
<40 000 758 (31) 93 (27)
40 000–79 999 743 (30) 110 (32)
80 000–120 000 308 (13) 48 (14)
4120 000 114 (4.6) 25 (7.4)
Missing 529 (22) 63 (19)
Body Mass Index (kg/m2)
Underweight<18.5 93 (3.8) 10 (2.9)
Normal 18.5–25 1446 (59) 169 (50)
Overweight 25–30 680 (28) 120 (35)
Obese and morbidly obese 530 228 (9.3) 40 (12)
Missing 5 (0.2) none
Positive history of hepatitis C
virus risk factors (more than
one could be mentioned)
Injection drug use 1386 (57) 134 (40)
Invasive medical procedurea 858 (35) 134 (40)
Transfusionb 559 (23) 92 (27)
Reported hepatitis C virus
positive sexual partner
321 (13) 28 (8.3)
Accidental needlestick 256 (10) 25 (7.4)
Professional exposure to blood 186 (7.6) 24 (7.1)
Living with hepatitis C virus
positive person
(not a sexual partner)
123 (5.0) 11 (3.2)
None recorded 231 (9.4) 63 (19)
Alcohol consumption
(ever having drunk
this quantity)
420 g alcohol per day 1382 (56) 158 (47)
420–40 g alcohol per day 357 (15) 40 (12)
440 g alcohol per day 679 (28) 131 (39)
Missing 34 (1.4) 10 (2.9)
Comorbidity
Diabetes 94 (3.8) 33 (9.7)
(continued)
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indicated liver biopsy were documented and graded as activity
of chronic hepatitis (none, minimal, mild, moderate, severe)
and fibrosis (none, portal fibrosis, portal fibrosis with rare
septa, bridging fibrosis, probable or definite cirrhosis).
Completed questionnaires and other information-gathering
forms were collected and kept centrally, at the Centre
Hospitalier Universitaire Vaudois in Lausanne, where they
were checked for completeness and correctness. If inconsisten-
cies were found or corrections were thought to be necessary,
then the form/s were sent back to the physician for amend-
ment. Finally, data were entered onto a computer database by
a person with paramedical training.
Laboratory procedures
Each treating physician was responsible for collecting clinical
and laboratory data as well as taking blood specimens
Table 1 Continued
Variable description
Total number (%)
(n¼ 2452)
Cirrhotics (%)
(n¼ 339)
Presence of other
infection markersc
Hepatitis A virus
antibody positive
1026 (42) 153 (45)
Missing 599 (24) 77 (23)
Ever infected with
hepatitis B virusd
946 (39) 132 (39)
Missing 76 (3.1) 15 (4.4)
Ever infected with hepatitis B
virus who were also hepatitis B
surface antigen positive
45 (1.8) 12 (3.5)
Human immunodeficiency virus
antibody positive
190 (7.8) 22 (6.5)
Missing 637 (26) 103 (30)
Information on hepatitis C
virus infection
Hepatitis C virus ribonucleic
acid positive
1565 (64) 191 (56)
Hepatitis C virus genotype
1 1128 (46) 171 (50)
2 206 (8.4) 27 (8)
3 654 (27) 81 (24)
4 213 (8.7) 28 (8.3)
5 3 (0.1) 0
6 3 (0.1) 1 (0.3)
Missing 242 (10) 31 (9.1)
Information at enrolment
on hepatitis C virus
associated disease
Ever had a liver biopsy 1235 (50) 257 (76)
Cirrhosis documented (clinical or
histological diagnosis)
339 (14) All cirrhotic
Missing 29 (1.2) NA
Primary liver cancer
(hepatocellular)
25 (1.0) 24 (7.1)
Alanine transaminase ratio
(ratio of laboratory value to
upper end of normal range)
41.0 824 (34) 80 (24)
41.0–2.5 930 (38) 129 (38)
52.5 568 (23) 110 (32)
Missing 130 (5.3) 20 (5.9)
History of hepatitis C virus
related treatment
Ever on drug treatment for
hepatitis C virus
752 (31) 173 (51)
Missing 220 (9) 27 (8)
Ever complementary medicine 173 (7.1) 36 (11)
a Includes acupuncture, autotransfusion, injection and dental treatment.
b Includes haemophilia and dialysis.
c Window of up to 180 days after enrolment date.
d Positive for 51 of the following: antibodies to hepatitis B core antigen,
hepatitis B surface antigen, hepatitis B e antigen, antibodies to hepatitis B e
antigen, hepatitis B virus deoxyribonucleic acid, antibodies to hepatitis D
virus. Excluded if positive for antibodies to hepatitis B surface antigen only.
 Anamnestic or documented.
 Window of 90 days either side of enrolment date.
Table 2 SCCS: summary of main variables collected via questionnaires
at enrolment and follow-up
Variable Source Enrolment Follow-up
Sociodemographic
Nationality SR X
Canton of residence SR X
Ethnicity SR X
Educational level attained SR X
Income (household) SR X
Occupational
Employment status SR X X
Health
Anthropometry
(weight and height)
X X
Hospital admission
in preceding
6 months
SR X X
Specific diseases SR X X
Parameters of liver
disease progression
SR and
documented
X X
Previous and ongoing
treatments for
hepatitis C
virus infection
SR and
documented
X X
Other blood test results Laboratory report X X
Peripheral blood
mononuclear cells
Frozen for future
genetic studies
X X
Health behaviours
Risk factors for
hepatitis C
virus acquisition
SR X
Injection drug use X Xa
Alcohol consumption SR X X
Psychosocial
Quality of life SR X X
a Time frame: since last visit.
 Time frame: ever
SR, self-reported; X, data collected.
Note: questions at enrolment and follow-up are not necessarily identical.
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from their patients. Blood tests performed at enrolment covered
aspects of general health, e.g. haemoglobin, parameters of
the hepatitis C virus infection (serum hepatitis C virus
ribonucleic acid levels), of hepatitis C virus-related liver disease
(levels of the liver enzyme alanine transaminase) and markers
indicating other past or current infections, e.g. hepatitis A and
B viruses and human immunodeficiency virus infection. Other
laboratory tests, e.g. liver function tests such as alanine
transaminase were done according to the laboratory’s standard
protocols in use at the time. We calculated raised alanine
transaminase ratios based on denominators that were the upper
end of the quoted normal range for the laboratory concerned.
All laboratories performed regular quality controls to assure
validity of their results.
Follow-up
At each follow-up visit, a separate questionnaire was
completed, which differed slightly from that at enrolment
(Table 2).
What is attrition like?
In addition to participants who moved away or retracted
their consent to be in the study, we considered participants as
lost to follow-up if s/he was not reported as dead and had not
been seen at a follow-up visit for more then 2.5 years. To apply
this definition correctly, we restricted this analysis to parti-
cipants who were registered before 1 January 2004 (total
of 1679) and used available follow-up information until
30 June 2006.
Of the 1679 persons registered by the 1 January 2004, we
classified 522 as losses to follow-up (31%). When compared
with all those enrolled in the cohort, participants lost to follow-
up were more likely to have been younger (median 39; inter-
quartile range, 29–42 years) and to have had injection drug
use as a reported risk factor. Regarding some of the clinical
features, 11% were cirrhotic and 25% had an alanine
transaminase level 2.5 times the upper limit of normal or
higher. They did not differ substantially regarding other
socio-demographic factors such as sex, ethnicity, nationality,
education and employment status.
What has it found? Key findings
In the near future, the SCCS is expected to provide more
substantive results addressing its aims and objectives. In this
baseline report, we were able to compare our findings to other
published international cohort studies of hepatitis C virus
infected persons.
Patient characteristics
Overall, our cohort is similar to other international cohorts
based on hospital patients. The mean age in the SCCS was
43 years, similar to a prospective cohort from France, where
the mean age was 45.3 years.11 The median age at diagnosis
(37, inter-quartile range, 30–46 years; Table 1) was similar to
the median age at reporting in the Swiss national surveillance
data (36, inter-quartile range, 29–46 years; based on
cumulative figures 1988–2005; Table 3).
Injection drug use was the most frequently reported risk
factor in the SCCS (57%), which compared with a hospital-
based British cohort that reported 64.5% injection drug use.12 In
the Swiss Federal Office of Public Health data, the most
commonly reported risk factor was also injection drug use (58%
of those who were not completely missing risk factor
information).
Most participants in the SCCS were males (63%), whites
(95%) and of Swiss nationality (75%). This was also in
accordance with data from the Swiss Federal Office of Public
Health, where the majority reported were males (61%) and
Swiss Nationals (73% of those with a given nationality). Other
health-care based cohort studies of hepatitis C virus infected
persons have shown a preponderance of males over females.
For example, studies by Mohsen, in the UK, had 68% males;12
Roudot-Thoraval in France had 59% males11 and Niederau in
Germany had 52% males.13
The genotype most commonly associated with injection drug
use is genotype 3.14 However, in our cohort the commonest was
genotype 1 (46%). This is interesting because, although the
majority reported injection drug use as a risk factor, many also
reported an invasive medical procedure and transfusion as risk
factors as well. Therefore, it may be through these other
Table 3 Hepatitis C cases reported to the Swiss Federal Office of Public
Health: physician reports 1988–2005
Variable description
Physician reports
1988–2005 (n¼ 28 941) (%)
Age at reporting (years)
Median (inter-quartile range) 36 (29–46) –
Missing 39 0.13
Gender
Male 17601 61
Missing 38 0.13
Nationality
Swiss 18459 64
Missing 4114 14
Positive history of hepatitis C
virus risk factors (more than
one could be mentioned)
Injection drug use 13116 45
Transfusion 2213 7.6
Dialysis 140 0.48
Contact with hepatitis C virus
positive person
1757 6.1
Sexual contact with hepatitis C
virus positive person
2896 10
Health care professional
(including accidental needlestick)
515 1.8
Othera 1032 3.6
Unknown/none identified 5039 17
Missing 6189 21
a Includes acupuncture, tattoo, piercing, surgery, endoscopy, injection,
dentist, professional exposure other than healthcare and ‘exposure abroad’.
 Based on data to 24 August 2006.
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exposures that the infections arose. It also has cost implications
for treatment because genotype 1 infections have a lower
success rate with pegylated interferon and ribavirin dual
therapy, with a 40–50% sustained viral response after a longer
period (48 weeks) of treatment, than genotypes 2 or 3 (80%
sustained viral response after 24 weeks).15
Amongst those documented as cirrhotic at enrolment (339 or
14% of all participants), a higher percentage reported ever
having drunk440 g of alcohol per day (39% of cirrhotics versus
28% of all participants). Of those who were cirrhotic at
enrolment, 24 (7%; 1% of all participants) already had a
diagnosis of a primary hepatocellular cancer. Other cohorts,
based on hospital patients with known hepatitis C virus
infection, have shown a range of 8.3–21.4% for cirrhotics and
1–3.6% for those with primary hepatocellular cancer within
which our proportions fall.11–13
Time to event analysis
We performed time-to-event analysis for a combined endpoint
of a new diagnosis of primary liver cancer or death from liver
cancer (ICD-10: C22). We used the reported date of the first
positive hepatitis C virus test as time zero, with participant
observation beginning at the date of enrolment (staggered entry
into the time-to-event analysis). Time of observation ended
with date of the event, the most recent date of a follow-up visit,
or the date of death; whichever came first. We then calculated
the rate for the combined endpoint by dividing the total
number of events by the total person-years of observation in
the SCCS and calculated 95% confidence intervals assuming a
Poisson distribution. This analysis was performed for all
participants and stratified for those with or without cirrhosis
at enrolment.
A total of 54 cases of a new primary hepatocellular cancer or
death due to liver cancer occurred since registration (to 30 June
2006), resulting in a crude event rate of 1.3/100 person-years
[95% confidence interval (CI) 0.98–1.7/100 person-years]. When
stratified by whether or not patients were cirrhotic at
enrolment, the crude death rate was 4.0/100 person years
(95% CI 2.7–5.9/100 person-years) for cirrhotics, which was 4.8
times higher (95% CI 2.8–8.2) than for non-cirrhotics. When
using the date of the first known anti-hepatitis C virus positive
test as time zero, we obtained a cumulative event risk, of
primary hepatocellular cancer or death from liver cancer, at 15
years of 19% (95% CI 14–26%).
Pathology of hepatitis C virus
There has been one publication to date, which has shown that
insulin resistance may play a role in fibrogenesis in patients
with chronic hepatitis C infected with genotypes other than
genotype 3.16
What are the main strengths and
weaknesses?
The SCCS study group is composed of an experienced team in
clinical, laboratory and epidemiological areas, who are well
placed to undertake the scientific agenda of the cohort and who
continuously review progress in terms of its aims and
objectives. The participants enrolled in the SCCS study came
from across Switzerland and had, at enrolment, a broad range
of demographic and clinical characteristics as shown by the
distribution of age at diagnosis, education, income, employment
and clinical features, e.g. hepatitis C virus genotype, alanine
transaminase levels and the presence of other infection
markers. When comparing the cohort with the Swiss national
surveillance data, the sample seemed similar in terms of age at
diagnosis, sex, nationality and the most frequently reported risk
factor is for hepatitis C virus infection. Therefore, its main
strengths are that it should provide generalizable results on the
progression of hepatitis C virus infection as well as facilitate the
conduct of targeted nested studies including those investigating
new treatment approaches. As the SCCS is a ‘purpose-built’
cohort, data collection has been standardized and is directly
comparable between centres as well as being available from a
single centralized database. International collaboration is
already happening and will strengthen findings by providing
a broader diversity of patients and opportunity for combining
datasets for analysis.
In the 4–6 years of operating, the number of participants
classified as lost to follow-up was substantial, especially among
individuals with a history of injection drug use. This might bias
findings if attrition is linked to disease severity and/or death. To
address this possible source of bias the recruitment centres,
together with the central data centre, will increase their efforts
to actively identify those who have not been seen for more than
2 years and encourage them to attend a follow-up visit.
The SCCS also appeared to enrol individuals with more severe
disease, probably because the majority came from secondary
and tertiary health care services. Despite this, the cohort should
still provide generalizable results, although efforts are being
made to recruit more patients from local networks. Finally, the
study is only in adults aged 18 years and over, so will not
provide information on infants and children.
Can I get hold of the data? Where can
I find out more?
The data and clinical samples are, in principle, available to all
researchers independently of their association with the SCCS.
All scientific projects intending to use data and/or clinical
samples from the SCCS must firstly be submitted as a ‘Letter of
Intent’, to the Scientific Committee (see subsequently) to be
evaluated. If deemed feasible and of sufficient scientific merit,
the author/s will be invited to submit a full proposal and access
to the data is granted after approval of the project. Since May 1
2004, the SCCS has been involved in the ViRgil (vigilance
against viral resistance) Network of Excellence, funded by the
European commission over 4 years (www.virgil-net.org). Thus,
external collaborations are positively encouraged, particularly
with other cohort studies, with ownership of data remaining
with the individual cohorts involved. Indeed, the ViRgil
network consists of 66 research groups throughout Europe
looking at how and why resistance to anti-viral drugs develops
in viruses in general, but initially focusing on three major
infectious diseases: hepatitis C virus, hepatitis B and influenza.
Scientific projects must be submitted in the form of a Letter
of Intent, with an estimate of resources required, to both the
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Chairman of the Scientific Committee (Prof. D. Moradpour)
and to the SCCS Chairman (Prof. F. Negro). For the addresses,
please see Appendix.
At present there is no dedicated website for the SCCS,
although this is currently under discussion.
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